Compare VanEck Australian Floating Rate ETF (FLOT) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
VanEck Australian Floating Rate ETF vs ResMed Inc. — how do they compare? VanEck Australian Floating Rate ETF trades at $50.97, while ResMed Inc. trades at $201.21 (market cap $28.80B). The key difference: ResMed Inc. pays a 1.21% dividend while VanEck Australian Floating Rate ETF pays none, and VanEck Australian Floating Rate ETF is trading nearer its 52-week high, ResMed Inc. nearer its low. Which is the better fit depends on your goals.
| FLOT | RMD | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $51.09 | $293.73 |
52-Week Low | $50.72 | $182.82 |
Market Cap | — | $28.80B |
Enterprise Value | — | $27.99B |
Dividend Yield | — | 1.21% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
ResMed (RMD) trades at $201.44, up 4.37% with strong earnings momentum after beating estimates for three consecutive quarters. The stock shows bearish technical signals but maintains robust fundamentals with 27.44% net margins and consistent revenue growth from $3.6B in 2022 to $5.15B in 2025. Recent strategic moves include divesting MatrixCare for $490M to sharpen focus on core sleep and respiratory care markets.
RMD presents a compelling growth story with analyst consensus pointing to 28% upside potential to $245.88. However, technical weakness and competitive pressures in the medical device space warrant caution. The company's strong cash flow generation and dividend payments provide shareholder value, but investors should monitor execution risks from the business portfolio restructuring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About VanEck Australian Floating Rate ETF
FLOT provides exposure to a diversified portfolio of Australian dollar-denominated floating rate notes. It tracks the Bloomberg AusBond Credit FRN 0+ Yr Index, focusing on high-quality, investment-grade bonds from top Australian banks and financial institutions.
Read more on FLOT →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
